Skip to main content

Antibody Mediated Rejection clinical trials at University of California Health

3 in progress, 1 open to eligible people

Showing trials for
  • BIVV020 (SAR445088) n Prevention and Treatment of Antibody-mediated Rejection (AMR)

    open to eligible people ages 18 years and up

    Primary Objectives: - Cohort A: To evaluate the efficacy of BIVV020 in prevention of AMR - Cohort B: To evaluate the efficacy of BIVV020 in treatment of active AMR Secondary Objectives: - To assess the overall efficacy of BIVV020 in prevention or treatment of AMR - To characterize the safety and tolerability of BIVV020 in kidney transplant participants - To characterize the pharmacokinetic (PK) profile of BIVV020 in kidney transplant participants - To evaluate the immunogenicity of BIVV020

    at UCLA UCSF

  • Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

    Sorry, in progress, not accepting new patients

    This trial investigates the efficacy and safety of clazakizumab [an anti-interleukin (IL)-6 monoclonal antibody (mAb)] for the treatment of CABMR in recipients of a kidney transplant.

    at UC Davis UCLA UCSF

  • VIRTUUS Children's Study

    Sorry, in progress, not accepting new patients

    The objective of the VIRTUUS Children's Study is to adapt identified and validated adult noninvasive diagnostic and prognostic biomarkers for the characterization of allograft status in pediatric recipients of kidney allografts.

    at UCLA UCSD

Our lead scientists for Antibody Mediated Rejection research studies include .

Last updated: